Novel therapeutic interventions for allergic rhinitis

Expert Opinion on Investigational Drugs

Volumn 15, Issue 12, 2006, Pages 1615-1625

  Passalacqua, Giovanni ^a   Ciprandi, Giorgio ^b  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

Allergen specific immunotherapy; Allergic rhinitis; Antihistamines; Corticosteroids; Immune response; Monoclonal antibodies

Indexed keywords

ALLERGEN; AZELASTINE; BECLOMETASONE; BUDESONIDE; CETIRIZINE; CICLESONIDE; CORTICOSTEROID; DECONGESTIVE AGENT; DESLORATADINE; EBASTINE; FEXOFENADINE; FLUNISOLIDE; FLUTICASONE; HISTAMINE; HISTAMINE H1 RECEPTOR; HISTAMINE H2 RECEPTOR; IMMUNOGLOBULIN E; IMMUNOGLOBULIN E RECEPTOR; LEUKOTRIENE RECEPTOR AFFECTING AGENT; LEVOCABASTINE; LEVOCETIRIZINE; LORATADINE; MOMETASONE FUROATE; OMALIZUMAB; PLACEBO; PROBIOTIC AGENT; ROFLUMILAST; TRIAMCINOLONE; UNINDEXED DRUG; VASOCONSTRICTOR AGENT;

ALLERGIC ASTHMA; ALLERGIC RHINITIS; ATROPHY; CELLULAR IMMUNITY; CLINICAL TRIAL; DISEASE ASSOCIATION; DISEASE CONTROL; DISEASE COURSE; DISEASE EXACERBATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CONTRAINDICATION; DRUG COST; DRUG EFFICACY; DRUG EXCRETION; DRUG FATALITY; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FIRST PASS EFFECT; GASTROINTESTINAL TOXICITY; HUMAN; IMMUNOTHERAPY; LAVAGE; LONG TERM CARE; META ANALYSIS; METABOLIC DISORDER; PATHOPHYSIOLOGY; PATIENT EDUCATION; PHENOTYPE; PRACTICE GUIDELINE; PRURITUS; RECEPTOR AFFINITY; REVIEW; RISK ASSESSMENT; RISK FACTOR; SYMPTOM; SYSTEMATIC REVIEW;

ALLERGENS; ANTI-ALLERGIC AGENTS; ANTI-ASTHMATIC AGENTS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL; ASTHMA; DESENSITIZATION, IMMUNOLOGIC; DRUG THERAPY, COMBINATION; DRUGS, INVESTIGATIONAL; FORECASTING; HUMANS; HYPERSENSITIVITY, IMMEDIATE; IMMUNOGLOBULIN E; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; PATIENT EDUCATION; PROBIOTICS; RHINITIS, ALLERGIC, PERENNIAL; RHINITIS, ALLERGIC, SEASONAL; SIGNAL TRANSDUCTION; TH2 CELLS;

EID: 33845209901     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.15.12.1615     Document Type: Review

References (102)

1. BOUSQUET J, VAN CAUWENBERGE P: Allergic Rhinitis and its Impact on Asthma (ARIA) WHO Position Paper. J. Allergy Clin. Immunol. (2001) 108(5 Part 2):S147-S334.
2. BJORKSTEN B, BRUNEKREEF B, COOKSON WO, VON MUTIUS E, STRACHAN DP: Phase II of the International Study of Asthma and Allergies in Childhood (ISAAC II): rationale and methods. Eur. Respir. J. (2004) 24:406-412.
3. BUGIANI A, CAROSSO A, MIGLIORE E et al: Allergic rhinitis and asthma comorbidity in a survey of young adults in Italy. Allergy (2005) 60:165-170.
4. TURKELTAUB PC: Prevalence of upper and lower respiratory conditions in the US population by social and environmental factors: data from the second National Health and Nutrition Examination Survey, 1976 to 1980 (NHANES II). Ann. Allergy (1991) 67:147-154.
5. MELTZER EO: Quality of life in adults and children with allergic rhinitis. J. Allergy Clin. Immunol. (2001) 108(1 Suppl.):S45-S53.
6. SCHOENWETTER WF, DUPCLAY L Jr, APPAJOSYULA S, BOTTEMAN MF, PASHOS CL: Economic impact and quality-of-life burden of allergic rhinitis. Curr. Med. Res. Opin. (2004) 20:305-317.
7. TRIPATHI A, PATTERSON R: Impact of allergic rhinitis treatment on quality of life. Pharmacoeconomics (2001) 19:891-899.
8. PAWANKAR R, YAMAGISHI S, TAKIZAWA R, YAGI T. Mast cell-IgE and mast cell-structural cell interactions in allergic airway disease. Curr. Drug Targets Inflamm. Allergy (2003) 2:303-312.
9. Allergy and allergic diseases. Second of two parts. N. Engl. J. Med. (2001) 344:109-113
10. CIPRANDI G, VIZZACCARO A, CIRILLO I, TOSCA M, MASSOLO A, PASSALACQUA G: Nasal eosinophils display the best correlation with symptoms, pulmonary function and inflammation in allergic rhinitis. Int. Arch. Allergy Immunol. (2005) 136:266-272.
11. H2 paradigm. Immunol. Today (1997) 18:263-266.
12. ROMAGNANI S: The role of lymphocytes in allergic disease. J. Allergy Clin. Immunol. (2000) 105:399-408.
13. CIPRANDI G, BUSCAGLIA S, PESCE GP et al.: Minimal persistent inflammation is present at mucosal level in asympromatic rhinitic patients with allergy due to mites. J. Allergy Clin. Immunol. (1995) 96:971-979
14. ROMAGNANI S: Regulatory T cells: which role in the pathogenesis and treatment of allergic disorders? Allergy (2006) 61:3-14.
15. TAYLORA, VERHAGEN J, ADKIS CA AKDIS M: T regulatory cells in allergy and health: a question of allergen specificity and balance. Int. Arch. Allergy Immunol. (2004) 135:73-82.
16. PASSALACQUA G, CIPRANDI G, GUERRA L, PASQUALI M, CANONICA GW. An update on the asthma-rhinitis link. Curr. Opin. Allergy Clin. Immunol. (2004) 4:177-183.
17. CRIMI E, MILANESE M, ODDERA S et al.: Inflammatory and mechanical factors of allergen-induced bronchoconstriction in mild asthma and rhinitis. J. Appl. Physiol. (2001) 91:1029-1034.
18. BRAUNSTAHL GJ: The unified immune system: respiratory tract-nasobronchial interaction mechanisms in allergic airway disease. J. Allergy Clin. Immunol. (2005) 115:142-148.
19. PASSALACQUA. G, CIPRANDI G, CANONICA GW. United airways disease: therapeutic aspects. Thorax (2000) 55(Suppl. 2):s26-s27.
20. DURHAM SR: Effect of intranasal corticosteroid treatment on asthma in children and adults. Allergy (1999) 54(Suppl. 57):124-131.
21. CRYSTAL-PETERS J, NESLUSAN C, CROWN WH, TORRES A: Treating allergic rhinitis in patients with comorbid asthma: the risk of asthma-related hospitalizations and emergency department visits. J. Allergy Clin. Immunol. (2002) 109:57-62.
22. NATIONAL INSTITUTES OF HFALTH: NHLBI/WMO Workshop Report: global strategy for asthma management and prevention (GINA). Bethesda: National Heart, Lung, and Blood Institute (1995) (Publication No. 95-3659).
23. GANI F, POZZI E, CRIVELLARO MA et al.: The role of patient training in the management of seasonal rhinitis and asthma: clinical implications. Allergy (2001) 56:65-68.
24. 2LEN). Allergy (2005) 60:1112-1115.
25. 1-antihistamines and inflammation. Clin. Exp. Allergy (2001) 31:1341-1343.
26. 1-antihistamines. N. Engl. J Med. (2004) 351:2203-2217.
27. PASSALACQUA G, ALBANO M, CANONICA GW et al.: Inhaled and nasal corticosteroids: safety aspects. Allergy (2000) 55:16-33.
28. LOCKEY RF, NIKOARA-KASTI GL, THEODOROPOULOS DS, BUKANTZ SC: Systemic reactions and fatalities associated with allergen immunotherapy. Ann. Allergy Asthma Immunol. (2001) 87(Suppl. 1):S46-S55.
29. COX L, LARENAS D, NOLTE H, WELDON D, FINEGOLD I: Sublingual immunotherapy: a comprehensive review. J. Allergy Clin. Immunol. (2006) 117:1021-1035.
30. World Health Organization position paper. Allergen immunotherapy: therapeutical vaccines for allergic diseases. Bousquet J, Lockey R, Mailing HJ (Eds). Allergy (1998) 53(Suppl. 72):3-13.
31. MALLING HJ, ABRFU-NOGUERA J, ALVAREZ-CUESTA E et al.: Local immunotherapy: position paper. Allergy (1998) 53:833-844.
32. MOLLER C, DREBORG S, FERDOUSI HA et al: Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J. Allergy Clin. Immunol. (2002) 109:251-256.
33. NOVEMBRE E, GALLI E, LANDI F et al.: Coseasonal sublingual immunotherapy reduces the development of asthma in children with allergic rhinoconjunctivitis. J. Allergy Clin. Immunol. (2004) 114:851-856.
34. CRAIG TJ, TEETS S, LEHMAN EB, CHINCHILLI VM, ZWILLICH C: Nasal congestion secondary to allergic rhinitis as a cause ofsleep disturbance and daytime fatigue and the response to topical nasal corticosteroids. J. Allergy Clin. Immunol. (1998) 101:633-637.
35. DENT G: Ciclesonide. Curr. Opin. Investig. Drugs (2002) 3:78-83.
36. KALINER MA: Pharmacologic characteristics and adrenal suppression with newer inhaled corricosteroids: a comparison of ciclesonide and fluticasone propionate. Clin. Ther. (2006) 28:319-331.
37. SZEFLER S, ROHATAGI S, WILLIAMS J et al.: Ciclesonide, a novel inhaled steroid, does not affect hypothalamic-pituitary-adrenal axis function in patients with moderate-to-severe persistent asthma. Chest (2005) 128:1104-1114.
38. POSTMA DS, SEVETTE C, MARTINAT Y, SCHLOSSER N, AUMANN J, KAFE H: Treatment of asthma by the inhaled corticosteroid ciclesonide given either in the morning or evening. Eur. Respir. J. (2001) 17:1083-1088.
39. CHAPMAN KR, PATEL P, D'URZO AD et al.: Maintenance of asthma control by once-daily inhaled ciclesonide in adults with persistent asthma. Allergy (2005) 60:330-337.
40. BATEMAN E, KARPEL J, CASALE T, WENZEL S, BANERJI D: Ciclesonide reduces the need for oral steroid use in adult patients with severe, persistent asthma. Chest (2006) 129:1176-1187.
41. SCHMIDT BM, TIMMER W, GEORGENS AC: The new topical steroid ciclesonide is effective in the treatment of allergic rhinitis. J Clin. Pharmacol. (1999) 39:1062-1069.
42. Safety, tolerability, and exposure of ciclesonide nasal spray in healthy and asymptomatic subjects with seasonal allergic rhinitis. J. Clin. Pharmacol. (2006) 46:461-467.
43. AHLSTROM-EMANUELSSON C, ANDERSSON M, PERSSON C, SCHREWELIUS C, GREIFF L: Topical treatment with aqueous solutions of rofleponide palmirate and budesonide in a pollen-season model of allergic rhinitis. Clin. Exp. Allergy (2004) 34:731-735.
44. CHANG TW, DAVIS FM, SUN NC et al: Monoclonal antibodies specific for human IgE producing cells: a potential therapeutic for IgE mediated diseases. Bio. Technology (1990) 8:122.
45. MANKAD VS, BURNS W. Omalizumab: other indications and unanswered questions. Clin. Rev. Allergy Immunol. (2005) 29:17-30.
46. CASALE TB, BERNSTEIN IL, BUSSE W et al.: Use of an antiIgE monoclonal antibody in ragweed induced allergic rhinitis. J. Allergy Clin. Immunol. (1997) 100:110-121.
47. CHERVINSKY P, CASALE T, TOWNLEY R et al.: Omalizumab, an anti-IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitis. Ann. Allergy Asthma Immunol. (2003) 91:160-167.
48. CASALE TB, CONDEMI J, LA FORCE C et al: Effect of omalizumab on symptoms of seasonal allergic rhinitis: a randomized controlled trial. JAMA (2001) 286:2956-2967.
49. ADELROTH E, RAK S, HAATELA T et al.: Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis. J. Allergy Clin. Immunol. (2000) 106:253-259.
50. KOPP MV, BRAUBURGER J, RIEDINGER F et al.: The effect of anti-IgE treatment on in vitro leukotriene release in children with seasonal allergic rhinitis. J Allergy Clin. Immunol. (2002) 110:728-735.
51. VIGNOLA AM, HUMBERT M, BOUSQUET J et al.: Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR. Allergy (2004) 59:709-717.
52. OBA Y, SALTZMAN GA: Cost-effectiveness analysis of omalizumab in adults and adolescents with moderate-to-severe allergic asthma. J. Allergy Clin. Immunol. (2004) 114:265-269.
53. KALINER MA: Omalizumab and the treatment of allergic rhinitis. Curr. Allergy Asthma Rep. (2004) 4:237-244.
54. TILL SJ, DURHAM SR: Immunological responses to allergen immunotherapy. Clin. Allergy Immunol. (2004) 18:85-104.
55. + T cells by grass pollen immunotherapy. J. Allergy Clin. Immunol. (2003) 111:1255-1261.
56. ABRAMSON M, PUY RM, WEINER J: Allergen immunotherapy for asthma. Cochrane Database Syst. Rev. (2003) 4:CD001186.
57. PASSALACQUA G, GUERRA L, PASQUALI M, LOMBARDI C, CANONICA GW. Efficacy and safety of sublingual immunotherapy. Ann. Allergy Asthma Immunol. (2004) 93:3-12.
58. WILSON D, LIMA MT, DURHAM SR: Sublingual immunotherapy for allergic rhinitis: systematic review and meta-analysis. Allergy (2005) 60:4-12.
59. DI RIENZO V, MUSARRA A, SAMBUGARO R et al.: Post marketing survey on the safety of sublingual immunotherapy in children below the age of 5 years. Clin. Exp. Allergy (2005) 35:560-564.
60. FIOCCHI A, PAJNO G, LA GRUTTA S et al.: Safety of sublingual-swallow immunotherapy in children aged 3 to 7 years. Ann. Allergy Asthma Immunol. (2005) 95:254-258.
61. COSMI L, SANTARLASCI V, ANGELI R et al.: Sublingual immunotherapy with Dermatophagoides monomeric allergoid down-regulates allergen-specific immunoglobulin E and increases both interferon-γ- and interleukin-10 production. Clin. Exp. Allergy (2006) 36:261-272.
62. CIPRANDI G, FENOGLIO D, CIRILLO I et al.: Induction of interleukin 10 by sublingual immunotherapy for house dust mites: a preliminary report. Ann. Allergy Asthma Immunol. (2005) 95:38-44.
63. HUNTER RL: Overview of vaccine adjuvants: present and future. Vaccine (2002) 20(Suppl. 3):S7-S12.
64. BALDRICK P, RICHARDSON D, ELLIOT G, WHEELER A. Safety evaluation of MPL, an immunostimulatory adjuvant. Regul. Toxicol Pharmacol. (2002) 35:398-413.
65. DRACHENBER KJ, WHEELER A, STUBNER P, HORAK F: A well tolerated grass pollen specific allergy vaccine containing a novel adjuvant MPL reduces allergy symptoms after only four preseasonal injections. Allergy (2001) 56:498-505.
66. SIMONS FE, SHIKISHIMA Y, VAN NEST G, EIDEN JJ, HAYGLASS KT. Selective immune redirection in humans with ragweed allergy by injecting Amb a 1 linked to immunostimulatory DNA. J. Allergy Clin. Immunol. (2004) 113:1144-1151.
67. CRETICOS PS, EIDEN JJ, BROIDE DH et al.: Immunotherapy with Immunostimulatory oligonucleotides; linked to purified ragweed Amb a1 allergen: effects on antibody production, nasal allergen provocation, and ragweed seasonal rhinitis. J. Allergy Clin. Immunol. (2002) 109:743-744.
68. JUTEL M, JAEGER L, SUCK R, MEYER H, FIEBIG H, CROMWELL 0: Allergen-specific immunotherapy with recombinant grass pollen allergens. J Allergy Clin. Immunol. (2005) 116:608-613.
69. OLDFIELD WL, LARCHÉ M, KAY AB: A double blind placebo controlled study of short-peptides derived from Fel d 1 iN cat allergic subjects. Lancet (2002) 360:47-53.
70. HORNER AA, TAKABAYASHI K, ZUBELDIAJM, RAZ E: Immunostimulatory DNA based therapeutics for experimental and clinical allergy. Allergy (2002) 57:24-29.
71. KAUR IP, CHOPRA K, SAINI A: Probiorics: potential pharmaceutical applications. Eur. J Pharm. Sci. (2002) 15:1-9.
72. WANKE CA: Do probiotics prevent childhood illnesses? Br Med. J (2001) 322:1318-1319.
73. MAJAMAA H, ISOLAURI E: Probiotics: a novel approach in the management of food allergy. J. Allergy Clin. Immunol. (1997) 99:179-85.
74. KALLOMAKI M, SALMINEN S, ARVILOMMI H et al.: Probiotics in primary prevention of atopic disease: a randomised placebo controlled trial. Lancet (2001) 357:1076-1079.
75. MARTINEZ FD, HOLT PG: Role of microbial burden in aetiology of allergy and asthma. Lancet (1999) 354(Suppl. 2):12-15.
76. SANFILIPPO L, LI CK, SETH R et al: Bacceroides fragilis enterotoxin induces the expression of IL8 and TGFβ by human colonic epithelia] cells. Clin. Exp. Immunol. (2000) 119:456-463.
77. GASKINS HR: Immunological aspects of host/microbiota interactions at the intestinal epithelium. In: Gastrointestinal microbiology. Mackie RJ, White BA, Isaacson RE (Eds), International Thomson Publishing, New York, USA (1997):537-587.
78. BULLENS DMA, VAN DEN KEYBUS, DILISSEN E et al.: Allergen-specific T cells from birch-pollen-allergic patients and healthy controls differ in T helper 2 cytokine and in IL-10 production. Clin. Exp. Allergy (2004) 34:879-887.
79. CIPRANDI G, VIZZACCARO A, CIRILLO I, TOSCA MA: Bacillus clausii effects in children with allergic rhinitis. Allergy (2005) 60:702-703.
80. CORRY DB, KHERADMAND F: Control of allergic airway inflammation through immunomodulation. J. Allergy Clin. Immunol. (2006) 117(Suppl. 2):S461-S464 (Mini Primer).
81. SUWAKI T, AGRAWAL DK, TOWNLEY RG: Modification of eosinophil function by suplatast tosilate (IPD), a novel anti-allergic drug. Int. ImmunoPharmacol. (2001) 1:2163-2171.
82. SANO T, NAKAMURA Y, YANAGAWA H et al.; HIGASHISHIKOKU ASTHMA RESEARCH GROUP: Add-on effects of suplatast tosilate in bronchial asthma patients treated with inhaled corticosteroids. Lung (2003) 181:227-235.
83. WASHIO Y, OHASHI Y, TANAKA A et al.: Suplatast tosilate affects the initial increase in specific IgE and interleukin-4 during immunotherapy for perennial allergic rhinitis. Acta Otolaryngol. Suppl. (1998) 538:126-132.
84. h2 pathway by suplatast tosilate in patients with perennial nasal allergies. Am. J. Rhinol. (2002) 16:329-336.
85. BOGUNIEWICZ M, SCHNEIDER LC, MILGROM H et al: Treatment of steroid-dependent asthma with recombinant interferon-γ. Clin. Exp. Allergy (1993) 23:785-790.
86. KON OM, SIHRA BS, COMPTON CH, LEONARD TB, KAY AB, BARNES N: Randomised dose-ranging placebo controlled study of chimeric antibody to CD4 (keliximab) in chronic severe asthma. Lancet (1998) 352:1109-1113.
87. BRYAN SA, O'CONNOR BJ, MATTI S et al.: Effects of recombinant human interleukin-12 on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet (2000) 356:2149-2153.
88. SCHMIDT BM, KUSMA M, FEURING M et al.: The phosphodiesterase 4 inhibitor roflumilast is effective in the treatment of allergic rhinitis. J. Allergy Clin. Immunol. (2001) 108:530-536.
89. ERIN EM, LEAKER BR, ZACHARASIEWICZ A et al.: Effects of a reversible beta-tryptase and trypsin inhibitor (RWJ-58643) on nasal allergic responses. Clin. Exp. Allergy (2006) 36:458-464.
90. 1 receptor-specific histamine antagonist, to loratadine 10 mg in the treatment of seasonal allergic rhinitis. J. Investig. Allergol. Clin. Immunol. (2004) 14:34-40.
91. KUDLACZ EM: Combined tachykinin receptor antagonists for the treatment of respiratory diseases. Expert Opin. Investig. Drugs (1998) 7(7):1055-1062.
92. WILSON AM, ORR LC, SIMS EJ, LIPWORTH BJ: Effects of monotherapy with intra-nasal corticosteroid or combined oral histamine and leukotriene receptor antagonists in seasonal allergic rhinitis. Clin. Exp. Allergy (2001) 31:61-68.
93. NAYAK AS, PHILIP G, LU S, MALICE MP REISS TF; MONTELUKAST FALL RHINITIS INVESTIGATOR GROUP: Efficacy and tolerability of montelukast alone or in combination with loratadine in seasonal allergic rhinitis: a multicenter, randomized, double-blind, placebo-controlled trial performed in the fall. Ann. Allergy Asthma Immunol. (2002) 88:592-600.
94. DI LORENZO G, PACOR ML, PELLITTERI ME et al.: Randomized placebo-controlled trial comparing fluticasone aqueous nasal spray in mono-therapy, fluticasone plus cetirizine, fluticasone plus montelukast and cetirizine plus montelukast for seasonal allergic rhinitis. Clin. Exp. Allergy (2004) 34:259-267.
95. BOUSQUET J, GAUCRIS S, KOCEVAR VS et al.: Increased risk of asthma attacks and emergency visits among asthma patients with allergic rhinitis: a subgroup analysis of the improving asthma control trial. Clin. Exp. Allergy (2005) 35:723-727.
96. PRICE DB, SWERN A, TOZZI CA, PHILIP G, POLOS P: Effect of montelukast on lung function in asthma patients with allergic rhinitis: analysis from the COMPACT trial. Allergy (2006) 61:737-742.
97. 2-agonists in patients with seasonal allergic rhinitis and asthma. Int. Arch. Allergy Immunol. (2003) 130:307-313.
98. REINARTZ SM, OVERBEEK SE, KLEINJAN A et al.: Desloratadine reduces systemic allergic inflammation following nasal provocation in allergic rhinitis and asthma patients. Allergy (2005) 60:1301-1307.
99. LEE DK, GRAY RD, WILSON AM, ROBB FM, SOUTAR PC, LIPWORTH BJ: Single and short-term dosing effects of levocetirizine on adenosine monophosphate bronchoprovocation in atopic asthma. Br. J. Clin. Pbarmacol. (2004) 58:34-39.
100. FAILLA M, BIONDI G, PROVVIDENZA PISTORIO M et al.: Intranasal steroid reduces exhaled bronchial cysteinyl leukotrienes in allergic patients. Clin. Exp. Allergy (2006) 36:325-330.
101. NATHAN RA, YANCEY SW, WAITKUS-EDWARDS K et al.: Fluticasone propionate nasal spray is superior to montelukast for allergic rhinitis while neither affects overall asthma control. Cbest (2005) 128:1910-1920.
102. CRYSTAL-PETERS J, NESLUSAN C, CROWN WH, TORRES A: Treating allergic rhinitis in patients with comorbid asthma: the risk of asthma-related hospitalizations and emergency department visits. J. Allergy Clin. Immunol. (2002) 109(1):57-62.